Enterovirus

SINOVAC Reports Unaudited Second Half of 2023 Financial Results and Files 2023 Annual Report on Form 20-F

Retrieved on: 
Monday, April 29, 2024
Biotechnology, General Health, Infectious Diseases, Health, Pharmaceutical, Heng, NMPA, The Twelve Months, Vaccine, Enterovirus, District court, Court, GAAP, Person, EV71, WHO, Hearing, National Medical Products Administration, Hand, Exchange, Complaint, Sinovac Biotech, Privy council, Good, Annual report, Influenza, Infection, OrbiMed, Motion, Foot, Judgement, Rights, GMP, Clinical trial, Government, Appellate court, Medication, Capital, Ageing, Influenza vaccine, Cancer, Trust, Bank statement, HFMD, COVID-19, Growth, Hepatitis

The Company also reported its unaudited financial results for the second half and audited financial for the full year ended December 31, 2023.

Key Points: 
  • The Company also reported its unaudited financial results for the second half and audited financial for the full year ended December 31, 2023.
  • Sales for the second half of 2023 were $307.9 million, compared to $280.5 million in the prior year period.
  • R&D expenses in the second half of 2023 were $193.4 million, compared to $257.7 million in the prior year period.
  • The Company’s financial statements for the second half of 2023 are prepared and presented in accordance with U.S. GAAP.

Most people who think they are allergic to penicillin aren't

Retrieved on: 
Wednesday, October 4, 2023
Infection, Review, Allergy, Rash, Ear, Life, Clostridioides difficile, Method, Royal Pharmaceutical Society, Fever, MRSA, Germ, Medicine, Diarrhea, Sickle cell disease, Vomiting, Death, Pharmacist, Anti-transglutaminase antibodies, Patient, Swelling, Anaphylaxis, Child, Risk, Nursing, Amoxicillin, Health, Penicillin, Bacteria, Throat, Roger Hawkins (drummer), GP, Pneumonia, Mouth, Respiratory failure, Pharmaceutical industry, Antibiotics, Vaccine, Enterovirus

Allergies vary between us, but someone allergic to penicillin typically develops a rash, itching and swelling.

Key Points: 
  • Allergies vary between us, but someone allergic to penicillin typically develops a rash, itching and swelling.
  • Typically, it is made when using penicillin to treat a feverish child with signs of an infected ear or throat.
  • This is done because someone allergic to penicillin typically responds badly to the next dose of penicillin, which can include the potentially lethal condition known as anaphylaxis.
  • If you think you have a penicillin allergy it would be wise to discuss and confirm this with your doctor.

epocrates Celebrates Sizable 2022 Growth, Driven by New Design, Tools, and Guidelines to Improve the Clinician Experience

Retrieved on: 
Thursday, March 2, 2023
Health, Apps, Applications, Technology, Health Technology, Mobile, Wireless, Pharmaceutical, Biotechnology, United States Department of Health and Human Services, Growth, News, RSV, Yoy, COVID-19, CDC, Mpox, Enterovirus, Apixaban, Infection, HIV, Amlodipine, DHHS, Atorvastatin, Mobile phone, Pharmaceutical industry

Notably, epocrates redesigned its mobile app to further improve the clinician experience, streamlining access to the many tools clinicians rely on at the point of care and beyond.

Key Points: 
  • Notably, epocrates redesigned its mobile app to further improve the clinician experience, streamlining access to the many tools clinicians rely on at the point of care and beyond.
  • Since the redesign in May 2022, news views have increased 64% and interaction check usage has increased 59% pointing to major growth in both epocrates’ clinician engagement and usage.
  • As the nation’s clinician shortage intensifies, the remaining healthcare workforce is busier than ever and facing growing caseloads to keep up with patient demand.
  • In addition to supporting busy clinicians with a more user-friendly mobile app, epocrates also released several updates to its decision support tools and enhanced content in 2022.

Anna Jaques Hospital RNs Go Public with Concerns for Patient Safety Resulting from Lack of Needed Staff & Closure of Essential Services

Retrieved on: 
Tuesday, November 22, 2022
Internal bleeding, Carbone, Joint Commission, Legislature, Scan (company), Workplace, DPH, Multimedia, Beverly Hospital, Head, Nursing, Accreditation, Degenerative disease, Morale, MNA, Communication, ER, Health, CT, Culture, AJH, Hospital, Massachusetts Department of Public Health, CNA, Stretcher, Public health, Safety, Enterovirus, Rhinovirus, EMS, RN, Critical care, Nuclear medicine, Nick Caserio, Stroke, Joint, Family, ED, Emergency, Patient, Risk, Commonwealth, RNS, Transesophageal echocardiogram, United States Army Hospital Corps, Medicine, Medical imaging, Health care

NEWBURYPORT, Mass., Nov. 22, 2022 /PRNewswire/ -- Registered nurses at Beth Israel Lahey Anna Jaques Hospital (AJH) are sounding the alarm about the safety of patient care at the facility due to the lack of needed staff in a number of departments and the recent decisions by the hospital administration to close essential services, including the decision last year to close the hospital's pediatric unit and the periodic closure of the hospital's Computer Tomography (CT) scanning service. 

Key Points: 
  • In response, nurses report that hospital management has done nothing to address the conditions, which have only gotten worse.
  • "We were also concerned that while the CT service was closed, the public and our patients were not informed of that fact," Carbone said.
  • After a public hearing on the closure, the state's Department of Public Health, deemed the service "essential" for the health of the community.
  • To date, AJH's administration has turned a deaf ear to the nurses' concerns and their efforts to address the nurses' concerns.

Element Introduces New Element LoopSeq™ Long-Read Sequencing Kits Designed for the AVITI™ System

Retrieved on: 
Thursday, November 10, 2022
SAN, RNA transfection, Genomics, Protein, WBE, Doctor of Philosophy, DNA sequencer, Research, Element, Virus, Science, Engineering, Sunday Faleye, CEO, Acquisition, Arizona State University, Bachelor of Engineering, COVID-19, Video game console, Vaccine, Enterovirus

SAN DIEGO, Nov. 10, 2022 /PRNewswire/ -- Element Biosciences, Inc.— developer of an innovative DNA sequencing platform disrupting the genomics industry — today announced the availability of its Element LoopSeq long-read sequencing technology kits for AVITI, giving the Element AVITI System the power of both short- and long-read sequencing on the same instrument. Element is the first company to own a general purpose long-read technology that runs on its native short-read sequencer.

Key Points: 
  • SAN DIEGO, Nov. 10, 2022 /PRNewswire/ -- Element Biosciences, Inc. developer of an innovative DNA sequencing platform disrupting the genomics industry today announced the availability of its Element LoopSeq long-read sequencing technology kits for AVITI, givingthe Element AVITI System the power of both short- and long-read sequencing on the same instrument.
  • Element LoopSeq is an extraordinarylong-read sequencing chemistry that provides synthetic long-read capabilities on AVITI.
  • For microbiome researchers, 16S LoopSeq for AVITI enables full-length 16S sequencing for up to 96 samples on the AVITI system.
  • Register here: https://www.elementbiosciences.com/events/webinar-beyond-covid
    For more information about Element LoopSeq, other LoopSeq kits and the AVITI System, including detailed specifications, application data, and performance testimonials, visit www.elementbiosciences.com
    Element Biosciences is a multi-disciplinary life science company developing disruptive DNA sequencing technology for research and diagnostic markets.

Get Vaccinated for COVID and Flu, Emergency Physicians Advise

Retrieved on: 
Thursday, October 20, 2022
People, CDC, Time, Hospital, Fatigue, Nausea, Urinary tract infection, Bronchitis, Vaccine, Pneumonia, COVID, RSV, Fellow of the American College of Emergency Physicians, Research, Emergency medicine, Attending physician, Emergency, Centers for Disease Control and Prevention, Center, Headache, Enterovirus, GLOBE, FACEP, Fever, American College, COVID-19, ACEP, Medicine, MD

Now is the right time to get a COVID vaccine and a flu shot, said Christopher S. Kang, MD, FACEP, president of ACEP.

Key Points: 
  • Now is the right time to get a COVID vaccine and a flu shot, said Christopher S. Kang, MD, FACEP, president of ACEP.
  • The Centers for Disease Control and Prevention (CDC), ACEP and other expert organizations advise annual flu vaccinations for anyone six months of age and older, with rare exceptions.
  • Flu shots are safe, effective, and getting vaccinated remains one of the easiest ways to protect against severe illness and hospitalization.
  • Some emergency physicians are seeing a recent uptick in children with respiratory infections, including RSV, a common virus that can cause lung infections, bronchitis, or pneumonia.

YDS Pharmatech helps uncover a novel viral recognition pathway: published in Nature Chemical Biology

Retrieved on: 
Thursday, August 18, 2022
YDS, Drug discovery, CEO, Molecule, AI, Nature Chemical Biology, Research, Membrane protein, Degenerative disease, Therapy, PROTAC, COVID-19, Tianjin Medical University, Norovirus, Plasma protein binding, Drug design, Ubiquitin, Virus, Enterovirus, Biology, MBA, Severe acute respiratory syndrome coronavirus 2, MD, LinkedIn, Vaccine

ALBANY, N.Y., Aug. 18, 2022 /PRNewswire/ -- YDS Pharmatech announced the publication of a paper revealing a novel human viral recognition mechanism in Nature Chemical Biology today.

Key Points: 
  • ALBANY, N.Y., Aug. 18, 2022 /PRNewswire/ -- YDS Pharmatech announced the publication of a paper revealing a novel human viral recognition mechanism in Nature Chemical Biology today.
  • The company helped reveal a new viral protein recognition mechanism, highlighting a promising new target for antiviral drugs.
  • Recently, TRIM7 was also shown to have activity against human enterovirus, but the mechanism by which TRIM7 recognizes viral proteins remained unknown.
  • In this study, YDS Pharmatech helped identify the specific molecular mechanism by which TRIM7 recognizes viral infection.

QIAGEN Launches Syndromic Test for QIAstat-Dx Device to Combat Global Monkeypox Health Emergency

Retrieved on: 
Monday, August 15, 2022
Health, Infectious Diseases, Clinical Trials, Research, Pharmaceutical, Science, U.S. Securities and Exchange Commission, Â, Monkeypox, Union, Public health, Laboratory, World Health Organization, Budget, VZV, NYSE, Senior, HSV2, Growth, SEC, Research, Life, Government, Blood, European, DNA, COVID-19, Infection, Urinary tract infection, QIAGEN, List of life sciences, HH6, RNA, RUO, Gold standard (test), Herpes labialis, Enterovirus, Knowledge, WHO, World, Automation, QGEN, Meningitis, Protein, Monkeypox virus, Molecular diagnostics, PCR, Solution, LDT, HSV1, Vaccine, Pharmaceutical industry, Insight

The new panel currently for research use only (RUO) comes in cartridge form to run on QIAGENs QIAstat-Dx automated syndromic testing devices.

Key Points: 
  • The new panel currently for research use only (RUO) comes in cartridge form to run on QIAGENs QIAstat-Dx automated syndromic testing devices.
  • Currently the worlds only syndromic test for the pathogen, the panel will prove to be crucial for detecting and then combatting the spread of monkeypox around the globe.
  • The panels RUO-status means it currently can only be used for the surveillance not screening or diagnosing of monkeypox cases.
  • QIAGEN teams around the world are working with healthcare authorities to support testing for the monkeypox virus outbreak.

Global Viral Transport Medium Market Report 2022-2027 Featuring Key Vendors - BD, Hardy DX, HiMedia Labs, Laboratory Corp of America, Puritan Medical Products, Thermo Fisher Scientific, & Vircell - ResearchAndMarkets.com

Retrieved on: 
Monday, August 8, 2022
Health, Infectious Diseases, FDA, Antibody, Herpes labialis, Mortality, Simplex, Diagnosis, Population, Growth, Chickenpox, RSV, SARS-COV-2, Hardy Diagnostics, Hospital, Prevalence, Research, Respiratory syncytial virus, Patient, Viral disease, Degenerative disease, COVID-19, Infection, Vaccine, Ageing, Transport, Nature, Enterovirus, Disease, Maintenance, PLOS, Solution, VTM, Collection, Pharmacy, Thermo Fisher Scientific, Animal, Pharmaceutical industry

More recently, the sudden onset of the COVID-19 pandemic significantly changed the demand for transport medium products and related kits.

Key Points: 
  • More recently, the sudden onset of the COVID-19 pandemic significantly changed the demand for transport medium products and related kits.
  • Owing to the surge in demand for diagnostic tests and sample collection from people, many vendors increased their production.
  • Most of the leading and emerging companies took part in fulfilling VTM supply across the healthcare system in the world.
  • The global viral transport medium market is highly competitive in nature due to the presence of domestic, regional, and international market players.

Altesa BioSciences to Initiate Clinical Trials of Promising Antiviral

Retrieved on: 
Thursday, May 26, 2022
FDA, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, Rhinovirus, Medical Affairs Bureau, Risk, Degenerative disease, Doctor of Philosophy, Infection, News, Patient, COPD, Food and Drug Administration, Â, Emory University, GA, DRIVE, Mortality, Trial of the century, FDA, IND, Partnership, Conference, Virus, Orthornavirae, RNA, Safety, Chronic obstructive pulmonary disease, Drug discovery, Respiratory tract, MD, Vaccine, Pharmaceutical industry, Health, Vaxart, Enterovirus, FDA, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology

Altesa BioSciences, Inc. (Altesa), a clinical-stage biopharmaceutical company developing and commercializing novel antiviral drugs against common respiratory viruses and global viral threats, has U.S. Food & Drug Administration approval to proceed with a clinical study of a promising antiviral treatment, vapendavir.

Key Points: 
  • Altesa BioSciences, Inc. (Altesa), a clinical-stage biopharmaceutical company developing and commercializing novel antiviral drugs against common respiratory viruses and global viral threats, has U.S. Food & Drug Administration approval to proceed with a clinical study of a promising antiviral treatment, vapendavir.
  • Accordingly, Altesa will initiate this trial and a series of others later this year and early next year, respectively.
  • The broad spectrum viral capsid inhibitor, vapendavir, is Altesas lead clinical stage antiviral drug, which was in-licensed in 2021.
  • Andrea True Kelly, PhD, Altesas Vice President of Clinical Development and Medical Affairs (formerly with Trimeris and Istari), said Altesa will initiate a clinical study this year to evaluate a new formulation of vapendavir.